How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon

After a brutal year of biotechs slashing programs and culling staff, the hottest topic at last week’s J.P. Morgan Healthcare conference was whether the frosty market is likely to thaw in 2023. But while some companies are counting every dollar, Fierce Biotech caught up with two CEOs of well-financed companies to find out how they are riding the rocky market waves and why they think they are well-positioned for the next few years.